Scottish Medicines Consortium issues guidance for use of Forxiga as type two diabetes therapy
Scottish Medicines Consortium (SMC) has issued advice that enables NHS Boards to allow physicians to prescribe Forxiga (dapagliflozin) as first-in-class type 2 diabetes treatment.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news